Know Your Surroundings: How Cancer Treatments Can Keep Cells From Supporting Tumors

By Eric Bender

Multiple myeloma is a poster child for recent advances in treatment: In the past decade, the U.S. Food and Drug Administration (FDA) approved no fewer than nine treatments for the blood cancer, and several more drug approvals appear to be near. Not coincidentally, multiple myeloma is also a popular target that researchers use to study the interactions of tumor cells and their “tumor microenvironments” — the non-cancerous cells, molecules and blood vessels that surround and often support the malignant cells.

Kenneth Anderson, MD

Kenneth Anderson, MD

“These new myeloma drugs are all based on understanding how the tumor cells interact with other cells in their bone marrow environment,” says Kenneth Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC).

Managing Myeloma

Multiple myeloma begins with mutations in the development of B cells — white blood cells that can turn into plasma cells that normally fight bacteria or viruses. The first clinical sign is a condition called monoclonal gammopathy of undetermined significance (MGUS), with abnormal plasma cells appearing in the bone marrow.

A small fraction of people with MGUS progress to smoldering myeloma, displaying higher populations of these cells. Most people with smoldering myeloma eventually develop active multiple myeloma, with low blood counts and increased risk of infection, kidney dysfunction, high blood calcium, and painful bone lesions.

Throughout the course of this disease, the interaction of these mutated plasma cells with their microenvironment is critically important.

“It’s called cell-adhesion mediated drug resistance, because binding of the tumor cell to the bone marrow triggers pathways mediating myeloma cell growth, survival and drug resistance,” Anderson says. “The novel agents overcome the conventional drug resistance that’s conferred by the microenvironment.”

Numerous types of nearby cells may be enlisted to aid the tumor, and thus may be targets for new agents. One example is plasmacytoid dendritic cells (pDCs), which normally alert the immune system to respond to a suspicious cell.

Cancer research, multiple myeloma

Along with Dana-Farber’s Kenneth Anderson, MD, and Kornelia Polyak, MD, PhD, Irene Ghobrial, MD (above), explores different aspects of the tumor microenvironment — the molecules, cells, and blood vessels that surround and support a tumor.

“In myeloma these pDCs do not stimulate immune responses as they should, and even worse, they promote tumor cell growth and drug resistance,” says Anderson. “So we are utilizing agents that target these pDC cells as potential myeloma therapies.”

In another project reported in 2014, researchers led by Irene Ghobrial, MD, demonstrated that in mice, an agent that blocked a protein known as stromal cell derived factor-1 (SDF-1), which is present in high levels in areas of the bone marrow with myeloma lesions, slowed the spread of the cancer and improved survival.

With this and many other research projects underway in her lab, “the whole idea is to reverse the way we think – instead of treating patients later on when the disease has progressed, can we change the microenvironment to prevent progression?” Ghobrial emphasizes. “We’re designing trials now to take the best drugs we have and bring them earlier to smoldering disease.

Stromal Surroundings

Tumor microenvironments are studied broadly and deeply in other blood cancers, and in many solid tumors as well. “In breast cancer, there’s a lot of data showing that the microenvironment is really important for tumor progression and for therapeutic resistance,” says Kornelia Polyak, MD, PhD, a breast cancer geneticist at DF/BWCC.

Breast cancer cells are surrounded by a “stroma” composed mostly of fibroblasts (the most common connective tissue cell), blood vessels, and immune system cells. “The stroma frequently makes the cancer cells more resistant to treatment,” says Polyak.

cancer research

Kornelia Polyak, MD, PhD

In one line of microenvironment research, Polyak’s lab is focusing on the role of fibroblasts from primary breast tumors and metastatic sites such as brain lesions that tend to be particularly resistant to treatment.

Other work examines the role of immune system cells in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.

Common Across Cancers

One key theme across cancers is the role of the microenvironment in metastasis, the spreading of cancer to additional parts of the body. For example, tumor cells secrete “exosomes”, tiny packages of protein and RNA that may help to seed metastases. Demonstrated in breast cancer, this phenomenon has been hypothesized to occur in myeloma as wellAnother common theme is the hope that drugs targeting the microenvironment may not need to be as selective as targeted drugs that seek out very specific mutations in tumor cells. Since the microenvironmental cells aren’t mutated, each type can be attacked as a population and it can’t develop resistance to drugs.

“If you look at the successful treatments in myeloma, they are not mutation-specific,” Ghobrial points out. For instance, proteasome inhibitors such as Velcade, which block the breakdown of proteins so that cells fill up with molecular garbage and die, “just kill any plasma cell,” she says.

“If you think about treatments for myeloma or breast cancers or other tumors directed against intrinsic abnormalities in the cancer cell, that gives you a number of opportunities,” Anderson sums up. “But if you target the host microenvironment or the interaction of the tumor with the microenvironment, you broadly expand the therapeutic options available.”

This article originally appeared in Dana-Farber’s Spring/Summer 2015 issue of Paths of Progress.  Read more from Paths of Progress, by downloading an issue for your iPad.

Comments Sort By Newest

2 thoughts on “Know Your Surroundings: How Cancer Treatments Can Keep Cells From Supporting Tumors

  1. This is great my suggestion on treatments, making a decision about treatment can feel overwhelming. In a short time, you are called upon to make critical decisions about your future, many of which are confusing and frightening. It is important to work together with your medical team to determine the best course of treatment for you. To work more effectively with your health care team, you should keep a notebook and schedule planner to track daily questions, side effects, notes, and appointment information. It will be helpful to bring someone with you to your appointments in order to manage all of the information and emotions

  2. I wondered if that was the same Eric Bender from IDG days. Looks like it! Hi Eric! I have a daughter interested in pursuing cancer research, so I am going to have her follow the DF blog. Hope all’s well. Bob still fishing and golfing and doing plenty of pro bono communications work for n

  3. I wondered if that was the same Eric Bender from IDG days. Looks like it! Hi Eric! I have a daughter interested in pursuing cancer research, so I am going to have her follow the DF blog. Hope all’s well. Bob still fishing and golfing and doing plenty of pro bono communications work for n

  4. This is great my suggestion on treatments, making a decision about treatment can feel overwhelming. In a short time, you are called upon to make critical decisions about your future, many of which are confusing and frightening. It is important to work together with your medical team to determine the best course of treatment for you. To work more effectively with your health care team, you should keep a notebook and schedule planner to track daily questions, side effects, notes, and appointment information. It will be helpful to bring someone with you to your appointments in order to manage all of the information and emotions

Comments are closed.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dana-Farber clinicians have been involved in the development of several new agents approved recently for B-cell acu… https://t.co/Oo3SiY79EN
Dana-Farber @danafarber
Dana-Farber #researchers have shown that clonal hematopoiesis of indeterminate potential (CHIP) - the presence of s… https://t.co/ZlmXSeyKfZ
Dana-Farber @danafarber
CRISPR, a powerful new tool for editing the #DNA instruction manual in animals and humans, is proving a boon to… https://t.co/pCzS3riHPS

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.